Published in Aging (Albany NY) on November 01, 2011
Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) (2012) 2.59
Answering the ultimate question "what is the proximal cause of aging?". Aging (Albany NY) (2012) 2.04
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle (2012) 1.53
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. Proc Natl Acad Sci U S A (2014) 1.31
pH neutralization protects against reduction in replicative lifespan following chronological aging in yeast. Cell Cycle (2012) 1.21
Geroconversion: irreversible step to cellular senescence. Cell Cycle (2014) 1.07
ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-kB-dependent activation of Snail. Oncotarget (2014) 1.07
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis (2013) 1.04
Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget (2014) 1.03
Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? Aging (Albany NY) (2012) 1.02
Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet. Cell Death Dis (2013) 1.02
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle (2013) 1.00
Role of mitochondrial reactive oxygen species in age-related inflammatory activation of endothelium. Aging (Albany NY) (2014) 0.98
Aging is not programmed: genetic pseudo-program is a shadow of developmental growth. Cell Cycle (2013) 0.98
mTORC1 and p53: clash of the gods? Cell Cycle (2013) 0.98
Phosphatidylethanolamine positively regulates autophagy and longevity. Cell Death Differ (2015) 0.97
ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer. Oncotarget (2015) 0.96
Hypoxia and gerosuppression: the mTOR saga continues. Cell Cycle (2012) 0.96
S6K in geroconversion. Cell Cycle (2013) 0.94
Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget (2015) 0.92
Acidosis promotes invasiveness of breast cancer cells through ROS-AKT-NF-κB pathway. Oncotarget (2014) 0.92
Tetrandrine induces autophagy and differentiation by activating ROS and Notch1 signaling in leukemia cells. Oncotarget (2015) 0.91
Macromitophagy is a longevity assurance process that in chronologically aging yeast limited in calorie supply sustains functional mitochondria and maintains cellular lipid homeostasis. Aging (Albany NY) (2013) 0.90
Yeast colonies: a model for studies of aging, environmental adaptation, and longevity. Oxid Med Cell Longev (2012) 0.90
The mitochondria-targeted antioxidant SkQ1 but not N-acetylcysteine reverses aging-related biomarkers in rats. Aging (Albany NY) (2012) 0.89
Chronological and replicative lifespan in yeast: do they meet in the middle? Cell Cycle (2012) 0.89
Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells. Oncotarget (2014) 0.88
M(o)TOR of aging: MTOR as a universal molecular hypothalamus. Aging (Albany NY) (2013) 0.88
Conserved role of medium acidification in chronological senescence of yeast and mammalian cells. Aging (Albany NY) (2011) 0.86
Recent discoveries in the cycling, growing and aging of the p53 field. Aging (Albany NY) (2012) 0.85
N-acetyl-cysteine prevents age-related hearing loss and the progressive loss of inner hair cells in γ-glutamyl transferase 1 deficient mice. Aging (Albany NY) (2016) 0.84
Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cells. Oncotarget (2015) 0.84
One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin. Aging (Albany NY) (2012) 0.83
Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss. Oncotarget (2014) 0.83
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle (2012) 0.83
MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer. Cell Cycle (2013) 0.82
Peroxisomal catalase deficiency modulates yeast lifespan depending on growth conditions. Aging (Albany NY) (2013) 0.81
Acetic acid and acidification accelerate chronological and replicative aging in yeast. Cell Cycle (2012) 0.81
Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway. Oncotarget (2015) 0.81
Dichloroacetate blocks aerobic glycolytic adaptation to attenuated measles virus and promotes viral replication leading to enhanced oncolysis in glioblastoma. Oncotarget (2015) 0.80
Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression. Oncotarget (2015) 0.79
Functional genomic analysis reveals overlapping and distinct features of chronologically long-lived yeast populations. Aging (Albany NY) (2015) 0.78
A new chronological survival assay in mammalian cell culture. Cell Cycle (2012) 0.78
Adaptive response to chronic mild ethanol stress involves ROS, sirtuins and changes in chromosome dosage in wine yeasts. Oncotarget (2016) 0.78
Chronological lifespan in stationary culture: from yeast to human cells. Aging (Albany NY) (2011) 0.78
Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells. Oncotarget (2015) 0.78
GSH-dependent antioxidant defense contributes to the acclimation of colon cancer cells to acidic microenvironment. Cell Cycle (2016) 0.77
TRIP-Br1 oncoprotein inhibits autophagy, apoptosis, and necroptosis under nutrient/serum-deprived condition. Oncotarget (2015) 0.77
EM23, a natural sesquiterpene lactone, targets thioredoxin reductase to activate JNK and cell death pathways in human cervical cancer cells. Oncotarget (2016) 0.77
Lactate promotes PGE2 synthesis and gluconeogenesis in monocytes to benefit the growth of inflammation-associated colorectal tumor. Oncotarget (2015) 0.77
Six plant extracts delay yeast chronological aging through different signaling pathways. Oncotarget (2016) 0.76
Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling. Oncotarget (2015) 0.76
A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis. Oncotarget (2016) 0.76
Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma. Oncotarget (2016) 0.75
Gerosuppression by pan-mTOR inhibitors. Aging (Albany NY) (2016) 0.75
Oxidative stress induced autophagy in cancer associated fibroblast enhances proliferation and metabolism of colorectal cancer cells. Cell Cycle (2016) 0.75
At neutral pH the chronological lifespan of Hansenula polymorpha increases upon enhancing the carbon source concentrations. Microb Cell (2014) 0.75
Co-regulation of polar mRNA transport and lifespan in budding yeast Saccharomyces cerevisiae. Cell Cycle (2012) 0.75
Tethering telomerase to telomeres increases genome instability and promotes chronological aging in yeast. Aging (Albany NY) (2016) 0.75
Loss of p16(INK4A) stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway. Oncotarget (2017) 0.75
Quercetin induced ROS production triggers mitochondrial cell death of human embryonic stem cells. Oncotarget (2016) 0.75
N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by (89)Zr-Trastuzumab and (18)F-FDG PET imaging. Oncotarget (2017) 0.75
Antihepatocarcinoma Effect of Portulaca oleracea L. in Mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB Pathway. Evid Based Complement Alternat Med (2017) 0.75
HSP90 inhibitor 17-DMAG exerts anticancer effects against gastric cancer cells principally by altering oxidant-antioxidant balance. Oncotarget (2017) 0.75
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
Extending healthy life span--from yeast to humans. Science (2010) 12.12
Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature (2004) 10.36
Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol (2004) 9.96
Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol (2010) 8.55
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev (2006) 6.62
Regulation of longevity and stress resistance by Sch9 in yeast. Science (2001) 5.93
The Akt-mTOR tango and its relevance to cancer. Cancer Cell (2005) 5.34
Role of BAX in the apoptotic response to anticancer agents. Science (2000) 5.07
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 4.69
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J (2007) 4.66
Reduced TOR signaling extends chronological life span via increased respiration and upregulation of mitochondrial gene expression. Cell Metab (2007) 4.59
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Sir2 blocks extreme life-span extension. Cell (2005) 4.25
With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab (2010) 4.11
The chronological life span of Saccharomyces cerevisiae. Aging Cell (2003) 3.98
Rapamycin decelerates cellular senescence. Cell Cycle (2009) 3.97
Sirtuins in aging and age-related disease. Cell (2006) 3.95
A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem (2003) 3.88
Delayed ageing through damage protection by the Arf/p53 pathway. Nature (2007) 3.87
Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A (2010) 3.81
Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle (2008) 3.37
Weak p53 permits senescence during cell cycle arrest. Cell Cycle (2010) 3.33
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27
MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in Saccharomyces cerevisiae. PLoS Biol (2007) 3.19
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A (2011) 3.14
Regulation of yeast chronological life span by TORC1 via adaptive mitochondrial ROS signaling. Cell Metab (2011) 3.13
A molecular mechanism of chronological aging in yeast. Cell Cycle (2009) 3.12
Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet (2007) 3.07
Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle (2010) 3.00
Pseudo-DNA damage response in senescent cells. Cell Cycle (2009) 2.93
Superoxide is a mediator of an altruistic aging program in Saccharomyces cerevisiae. J Cell Biol (2004) 2.88
The TOR pathway comes of age. Biochim Biophys Acta (2009) 2.83
Aging: ROS or TOR. Cell Cycle (2008) 2.82
Lessons on longevity from budding yeast. Nature (2010) 2.81
Mutations that increase the life span of C. elegans inhibit tumor growth. Science (2006) 2.48
Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle (2009) 2.45
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget (2010) 2.44
Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle (2006) 2.23
Tor1/Sch9-regulated carbon source substitution is as effective as calorie restriction in life span extension. PLoS Genet (2009) 2.18
Growth and aging: a common molecular mechanism. Aging (Albany NY) (2009) 2.13
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) (2010) 1.97
Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol (2009) 1.94
Extension of chronological life span by reduced TOR signaling requires down-regulation of Sch9p and involves increased mitochondrial OXPHOS complex density. Aging (Albany NY) (2009) 1.82
p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene (2000) 1.82
A method for high-throughput quantitative analysis of yeast chronological life span. J Gerontol A Biol Sci Med Sci (2008) 1.76
Chemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TOR-independent manner, by modulating housekeeping longevity assurance processes. Aging (Albany NY) (2010) 1.76
Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle (2010) 1.74
Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle (2010) 1.73
The chronological life span of Saccharomyces cerevisiae. Methods Mol Biol (2007) 1.72
Influence of genotype and nutrition on survival and metabolism of starving yeast. Proc Natl Acad Sci U S A (2008) 1.69
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle (2009) 1.68
The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim Biophys Acta (2010) 1.68
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Cell cycle arrest is not senescence. Aging (Albany NY) (2011) 1.57
Autophagy is required for extension of yeast chronological life span by rapamycin. Autophagy (2009) 1.57
p53, ROS and senescence in the control of aging. Aging (Albany NY) (2010) 1.56
EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget (2010) 1.53
Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging (Albany NY) (2009) 1.48
Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging (Albany NY) (2009) 1.46
Large-scale identification in yeast of conserved ageing genes. Mech Ageing Dev (2005) 1.43
Growth signaling promotes chronological aging in budding yeast by inducing superoxide anions that inhibit quiescence. Aging (Albany NY) (2010) 1.33
Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle (2011) 1.32
TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) (2010) 1.32
The Warburg effect suppresses oxidative stress induced apoptosis in a yeast model for cancer. PLoS One (2009) 1.31
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle (2009) 1.29
Paradigms and pitfalls of yeast longevity research. Mech Ageing Dev (2002) 1.26
Unlocking the secrets of longevity genes. Sci Am (2006) 1.24
Oncogene homologue Sch9 promotes age-dependent mutations by a superoxide and Rev1/Polzeta-dependent mechanism. J Cell Biol (2009) 1.23
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
Hot topics in aging research: protein translation and TOR signaling, 2010. Aging Cell (2011) 1.22
The mitochondrial ribosomal protein of the large subunit, Afo1p, determines cellular longevity through mitochondrial back-signaling via TOR1. Aging (Albany NY) (2009) 1.21
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (2010) 1.18
Dietary restriction: standing up for sirtuins. Science (2010) 1.17
Composition and acidification of the culture medium influences chronological aging similarly in vineyard and laboratory yeast. PLoS One (2011) 1.16
Quantitative evidence for early life fitness defects from 32 longevity-associated alleles in yeast. Cell Cycle (2011) 1.13
eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle (2010) 1.07
Targeting TOR dependence in cancer. Oncotarget (2010) 1.07
Ras: the other pro-aging pathway. Sci Aging Knowledge Environ (2004) 1.05
P53 and aging: A fresh look at an old paradigm. Aging (Albany NY) (2010) 1.05
Severe lactic acidosis in a patient with B-cell lymphoma: a case report and review of the literature. Case Rep Med (2010) 1.02
The hypoxic response and aging. Cell Cycle (2009) 1.00
Using yeast to discover the fountain of youth. Sci Aging Knowledge Environ (2001) 1.00
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget (2010) 0.98
The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle (2011) 0.97
Shifting senescence into quiescence by turning up p53. Cell Cycle (2010) 0.93
Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. Cell Cycle (2009) 0.92
Hyperinsulinemia and type 2 diabetes: impact on cancer. Cell Cycle (2010) 0.91
The sweet taste of death: glucose triggers apoptosis during yeast chronological aging. Aging (Albany NY) (2010) 0.89
Impact papers on aging in 2009. Aging (Albany NY) (2010) 0.89
Conserved role of Ras-GEFs in promoting aging: from yeast to mice. Aging (Albany NY) (2011) 0.85
Insulin/IGF-I and related signaling pathways regulate aging in nondividing cells: from yeast to the mammalian brain. ScientificWorldJournal (2010) 0.83
Fatal lactic acidosis due to leukemic transformation in a patient with non-Hodgkin's lymphoma: case report. Adv Ther (2006) 0.78
Ageing. Yeast longevity gene goes public. Nature (2001) 0.77
Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle (2011) 5.42
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Rapamycin decelerates cellular senescence. Cell Cycle (2009) 3.97
Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A (2010) 3.81
Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle (2008) 3.37
Weak p53 permits senescence during cell cycle arrest. Cell Cycle (2010) 3.33
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27
Pseudo-DNA damage response in senescent cells. Cell Cycle (2009) 2.93
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28
Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol (2010) 2.22
Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle (2009) 2.22
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) (2010) 1.97
Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A (2012) 1.83
Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) (2012) 1.79
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle (2009) 1.68
Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A (2002) 1.64
At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle (2009) 1.54
Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle (2012) 1.53
The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia. Mol Cell Biol (2002) 1.48
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) (2012) 1.47
Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging (Albany NY) (2009) 1.46
Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol (2012) 1.45
Suppression of replicative senescence by rapamycin in rodent embryonic cells. Cell Cycle (2012) 1.39
Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell (2014) 1.27
Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. Am J Pathol (2012) 1.22
The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1α. Cell Cycle (2011) 1.18
CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle (2013) 1.18
Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res (2004) 1.18
Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther (2005) 1.17
The interaction of p53 with replication protein A mediates suppression of homologous recombination. Oncogene (2004) 1.16
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res (2003) 1.15
Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY) (2012) 1.05
Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion. Oncogene (2005) 1.01
Rapamycin suppresses brain aging in senescence-accelerated OXYS rats. Aging (Albany NY) (2013) 1.01
Aging: past, present and future. Aging (Albany NY) (2009) 1.01
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene (2002) 0.98
Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. PLoS One (2011) 0.97
Hypoxia and gerosuppression: the mTOR saga continues. Cell Cycle (2012) 0.96
S6K in geroconversion. Cell Cycle (2013) 0.94
Cancer and aging: more puzzles, more promises? Cell Cycle (2008) 0.92
p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle (2007) 0.91
Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res (2005) 0.89
Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive. J Cell Sci (2004) 0.88
Comparison of rapamycin schedules in mice on high-fat diet. Cell Cycle (2014) 0.87
The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. Cancer Biol Ther (2003) 0.86
Fasting levels of hepatic p-S6 are increased in old mice. Cell Cycle (2014) 0.86
The second international conference "genetics of aging and longevity". Aging (Albany NY) (2012) 0.77
Complementation of two mutant p53: implications for loss of heterozygosity in cancer. FEBS Lett (2005) 0.77
No restriction points in life and science. Cell Cycle (2002) 0.76
From cytometry to cell cycle: a portrait of Zbigniew Darzynkiewicz. Cell Cycle (2004) 0.75